Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma, Hepatocellular × liposomal doxorubicin × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 4 Fallopian Tube Neoplasms 4 Sarcoma 1 Ovarian Cancer Recurrent 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Hepatocellular 1

Interventions

Sorafenib 8 lenvatinib 5 apatinib 5 Oxaliplatin 5 Fluorouracil 5 sintilimab 4 Leucovorin 4 Folfox protocol 4 Bevacizumab 4 camrelizumab 3 atezolizumab 3 Capecitabine 3 tremelimumab 2 durvalumab 2 Radiosurgery 2 Nivolumab 2 Neoadjuvant Therapy 2 Injections 2 Hepatectomy 2 Gemcitabine 2 Ethiodized Oil 2 Drug Therapy 2 pirarubicin 1 menatetrenone 1 liposomal doxorubicin 1 lanreotide 1 halofantrine 1 donafenib 1 coenzyme Q10 1 budigalimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02527772 2019-06-04

LD-FOX4/HCC

Guangxi Medical University

Phase 2/3 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡